Male hormonal contraceptive methods require effective suppression of sperm output.
H
ormonal methods that exploit negative feedback suppression of pituitary gonadotropin secretion, analogous to ovulation inhibition by combined estrogen-progestin contraceptives, are effective and reversible (1) (2) (3) (4) (5) (6) (7) . Androgen or androgenprogestin treatment combinations can inhibit spermatogenesis to azoospermia (no sperm in ejaculate) or near-azoospermia (Յ1 million/ml semen), with some regimens being more effective than others (8 -16) . This degree of suppression of sperm output provides effective contraception with efficacy rates of 97-100% (1) (2) (3) (4) . Recovery of sperm output to levels consistent with normal male fertility can also be expected in all men (5) , and short-term safety parameters have been identified (17) .
Understanding the factors responsible for suppression of sperm output to levels that provide reliable contraception is essential for designing optimal regimens for male hormonal contraceptives. In particular, understanding which factors predict rapid suppression of sperm output is especially important for a practical method that couples may wish to switch to without delay. Conversely, identifying which men are likely to suppress sperm output more slowly is equally important to allow antecedent counseling.
Physiological studies in humans and other primates suggest biphasic effects are plausible because gonadotropin withdrawal impairs different stages of spermatogenesis both early (spermatogonial proliferation) and late (spermiation) in the spermatogenic cycle (18) . Different early, compared with late, rates of suppression of sperm output could thereby result. Previous work has implicated Asian (compared with Caucasian) ethnicity (19) , lower baseline FSH concentration and greater gonadotropin suppression (4, 20) , progestin coadministration (21, 22) , and lower testosterone dose (22, 23) in more complete eventual suppression of sperm output. However, available studies were limited by relatively small sample sizes, which precluded adequately powered multivariate analyses. An integrated analysis, combining data from all available sources, would allow assessment of the relative and independent importance of putative predictors.
We therefore conducted an integrated analysis of individual participant data to examine factors that may influence the extent and the rate of spermatogenic suppression, to define predictors. Such an analysis was feasible because of the inherent consistency of study design and the standardized methods used to assess the primary endpoint (semen analysis) arising from a long history of collaboration and information sharing among investigators active in the field, with regular meetings sponsored for three decades by the World Health Organization (WHO) and more recently by international summit meetings. These groups have, in addition, developed comprehensive international advisory recommendations related to the development of hormonal regimens of male fertility regulation (6, 24, 25) . We also recently analyzed the rate of recovery of spermatogenesis after hormonal methods are ceased (see Subjects and Methods) (5) . In the current analysis, we examined both the rate and extent of spermatogenic suppression stratifying on a time-dependent variable to distinguish early from later influences using data largely derived previously (5).
Subjects and Methods

Data collection, subjects, and interventions
Studies in which men were administered an androgen or androgenprogestin regimen for at least 3 months were initially identified by PubMed search using key terms "androgen" or "testosterone" with "contraception." An exposure period of at least 3 months was chosen because the spermatogenic cycle requires about 70 d to complete (26, 27) . Additional studies were located by scrutinizing reference lists and surveying members of the international hormonal male contraception summit group, which includes representatives of virtually all active clinical research groups studying male hormonal methods. All identified studies recruited healthy, eugonadal men on the basis of unremarkable reproductive history; physical examination (including testicular examination); blood hormonal, biochemical, and hematological parameters; and semen analysis (requiring two semen analysis with sperm concentration of at least 20 million/ml). Semen was consistently assessed by contemporaneous WHO-recommended methods (28) before and at least monthly (every 2-4 wk) during treatment in all studies. Baseline sperm concentration was defined as the mean sperm concentration from at least two individual semen analyses.
Thirty-four studies were identified at the time of data collection in 2005 (1-4, 23, 29 -57); however, four studies were excluded from the analysis because the necessary data were not available from study investigators (54 -57) . Since the time of data collection, two additional studies have been published (58, 59) (Tables 1 and 2) . Data from these two recent studies were not included in the current analysis. Deidentified individual subject data were supplied by investigators of 20 single-and 10 multicenter studies spanning five continents (North and South America, Europe, Asia, and Australia) through a standardized worksheet that was approved by the Harbor-UCLA Medical Center Institutional Review Board (Table 1) . Hence, about 85% of all individual subject data from all 36 published studies identified in 2007 were available for analysis, and the 30 included studies were similar to the six studies not included (Table 2) . In all clinical studies, prior written informed consent was obtained from each subject after approval from the relevant human subjects research ethics committee. Men were aged 18 -51 yr, were treated for 16 -78 wk with im testosterone (T), T undecanoate (TU), T decanoate (TD), T enanthate (TE); oral T capsule (TU); transdermal T patch; biodegradable T pellets; or 7-␣ methyl-19-nor-testosterone (MENT) acetate implants with or without oral cyproterone acetate (CPA), oral or implants of levonorgestrel (LNG), oral or injections of norethisterone (NET), oral desogestrel (DSG), implants of etonogestrel (ENG), or injections of depot medroxyprogesterone acetate (DMPA). As shown, studies were either efficacy studies (in which pregnancies/contraceptive failures was the end point) or suppression studies (in which the end point was sperm output). For efficacy studies, treatment ceased if suppression of sperm concentration to azoospermia, 1 million/ml or less or 3 million/ml or less did not occur by 6 months (1-4), and data were then censored statistically. For suppression studies, some of these were exploratory to determine best dose, delivery systems, or androgen-progestin combinations and hence were not optimized to ensure uniform suppression of spermatogenesis. Information was collected for the present analysis from 1756 men (from a potential group of 2023 recruited into all 30 studies) who were exposed to a hormonal regimen for fertility control for at least 3 months. Not all data were obtained from all recruited men. As previously mentioned, this report includes data from a subgroup of men in which recovery of spermatogenesis after cessation of hormonal exposure was additionally documented (5) . The primary end point (focal point) for the present study was time to suppress sperm output to a concentration of 1 million/ml or less. This degree of suppression is sufficient for reliable contraception (6) . Subjects were censored when they dropped out of the study. These times were extracted by one investigator (P.Y.L.) from complete databases containing all individual semen data supplied by investigators from Sydney, Australia; Mü nster, Germany; Los Angeles, CA; Seattle, WA; and WHO. These data comprise about half of all sperm threshold data. Extracted data were provided by the investigators for the remaining studies.
Baseline subject and treatment data that might influence suppression times a priori were also collected (Tables 3 and 4 ). All covariate data collected and used for this analysis are listed in these tables. 
Calculations
We calculated the effective daily T dose according to known pharmacokinetics of testosterone preparations (60 -63) . Calculation of daily effective dose is based on the following assumptions and mean values recognizing that there is considerable individual variation in pharmacokinetics. This was 5% of the administered dose for oral TU, 5 mg per patch for transdermal T and 1.3 mg per 200 mg T pellet. For im testosterone esters, the exact amount of T injected was calculated (using the known molecular weight of testosterone discounting the ester side chain) from which the total T dose administered over the entire nominal treatment period based on the injection frequency could be determined. From this the effective daily T dose was calculated.
Analysis
We examined the rate of suppression by means of an integrated reanalysis of individual subject data (64) , not a metaanalysis of pooled summary study data. Hence, the unit of analysis was the individual subject, not the 30 identified studies. Univariate analyses of continuous (Cox) and categorical (Kaplan-Meier) variables were initially performed and analogously to a recently applied analytical strategy (5). A parsimonious model was identified by stepwise selection and confirmed by best subset selection of all possible covariate combinations. The best subset selection method chooses a sequence of models with increasing number of predictors, each of which is most predictive among competitors with the same number of predictors. We examined suppression of sperm concentration from baseline to 1 million/ml or less. Finally, we examined whether early or late effects on sperm suppression might differ by creating a time-dependent covariate to dichotomize and on which to stratify the extended Cox analysis (64) .
As a separate analytical strategy, we also examined the extent of suppression of sperm output by dichotomizing men into those who did or did not ever suppress to a sperm concentration of 1 million/ml and assessed how they differed in baseline parameters (by two-sample Student t test or Fisher test for continuous and categorical variables, respectively). Significant variables were then analyzed simultaneously by stepwise multivariate logistic regression to identify independent predictive covariables.
All tests were two sided, with P Ͻ 0.05 considered significant. Data are shown as median (range) or mean Ϯ SEM. These analyses were executed with SAS proc phreg, lifetest, and logistic (version 9.1; SAS Institute, Inc., Cary, NC). Proportional hazards assumptions were confirmed by graphical examination of Schoenberg residuals and supremum and related tests (64) . Tables 3 and 4 show baseline characteristics of the 1756 men identified from 30 studies and the univariate (unadjusted) utility of these characteristics as predictors of spermatogenic suppression. For categorical variables, these inferences are similar to those obtained with Kaplan-Meier log-rank tests: androgen, ethnicity, and progestin use (each P Ͻ 0.001).
Results
Rate of suppression
A Kaplan-Meier (unadjusted) curve showing the proportion of men who suppressed their sperm concentrations to 1 million/ml or less was constructed (Fig. 1) . This indicated that sperm concentration first falls to 1 million/ml or less after a median time of 2.73 (2.70 -2.76 95% confidence interval) months. Figure 2 shows the multivariately adjusted hazard ratios and 95% confidence intervals of the final multivariate models selected after stepwise Cox regression from the potential set of all univariate variables (shown in Tables 3 and 4 ). Hazard ratios exceeding 1.0 indicate faster, whereas those less than 1.0 signify slower, rates of suppression. Considerable overlap of 95% con- fidence intervals for hazards ratios indicate the comparability among the different T preparations (P Ͻ 0.009 vs. MENT for each), except for oral and transdermal T which, as a group, is associated with slower suppression. Faster rates of suppression were observed in Caucasian men or with concurrent progestin administration. Slower suppression occurred with older age, higher baseline blood testosterone, or higher baseline sperm concentration (each significant P Ͻ 0.001); however, these adjusted effect sizes were relatively small (hazard ratio Ͼ 0.98, for each) in comparison with the expected range of each of these parameters. Next, we repeated the same analysis but allowed for the rate of suppression of sperm output to differ early or late in time. Early epoch of time was defined as earlier than 3 months, based on the Kaplan-Meier analysis, which showed that the median time to suppression was 2-3 months, and on the 2.5-month duration of the spermatogenic cycle. Similar results were obtained if the early epoch of time is defined as earlier than 2 months. These data (not shown) all indicate that predictors, except for ethnicity, are invariant across time. The hazard ratio for ethnicity, in contrast, was significantly greater than 1 [hazard ratio 1.8430 (1.5330 -2.2170), P Ͻ 0.0001] during the early time period but was significantly less than 1 [hazard ratio 0.5280 (0.4100 -0.6810), P Ͻ 0.0001] during the late time period. This means that the rate of suppression of sperm output in Caucasian men is faster, compared with Asian men, during the first 2-3 months of exposure but slower, compared with Asian men thereafter. Table 5 shows the univariate analyses examining differences between men who suppressed their sperm concentration to 1 million/ml (n ϭ 1513) from those who did not (n ϭ 243). Table  6 shows which of these variables are independently important by stepwise multivariate logistic regression. These analyses confirm the extended Cox analysis showing that the most important predictors of incomplete suppression based on effect size are Caucasian (vs. Asian) ethnicity and the use of androgen alone (vs. androgen with progestin) regimens. In addition, increasing obesity and exposure to a higher effective dose of testosterone in- Hazard ratios and 95% confidence intervals, with multivariate adjustment to exclude effects of other variables, are shown. Hazard ratios exceeding 1 indicate faster, whereas those less than 1 signify slower, rates of suppression for each unit increase in the corresponding variable. *, Hazard ratios that significantly differ from unity (vertical line). Note magnified hazard ratio scale for age, baseline sperm concentration, and baseline T. creases the odds of nonsuppression, but these effects were numerically less important.
Extent of suppression
Discussion
In this analysis, the most comprehensive of its kind, only six factors were independently identified as predicting the rate of suppression of sperm output, and only two factors (concurrent progestin use and ethnicity) are likely to be clinically important because of large effect size. The detection of these small effects (with hazard ratios of no less than 0.98 and therefore close to a no effect hazard ratio of 1) underscores the statistical power of the current data set and the methods of analysis. Furthermore, the highly significant inferences unveiled (often P Ͻ 10 Ϫ3 ) highlights that these relationships were not due to multiple comparisons. These findings also suggest that it is unlikely that conventional clinical or laboratory variables could be used to identify men a priori who are more or less likely to suppress sperm output to levels consistent with reliable male contraception. We conclusively show by both an extended Cox regression approach (to allow for time varying covariants) and multivariate logistic regression that progestin coadministration enhances both the rate and extent of spermatogenic suppression. For these reasons, a practical male hormonal method will require an androgen and progestin combination. An important caveat to this finding is that all progestins were considered equivalent for the purposes of this analysis to obtain an average progestin effect. In reality, progestins are likely to differ in their effects on the rate of suppression, but our data set had insufficient power for such a refined analysis because only about one third of the men received progestins, and only a few of the possible androgen-progestin combinations were applied. Progestins are known to differ according to rodent antiovulatory potency, ability to support pregnancy, and binding and activation of progesterone (and other steroid) receptors in various cell systems (65) . How these differences translate to suppression of sperm output will ultimately require direct comparison through future experimentation among leading androgen and progestin combination candidate regimens to resolve this question.
The various T preparations examined exerted remarkably similar effects on spermatogenic suppression; increasing effective testosterone dose was a minor but significant predictor of nonsuppression, independent of concurrent progestin use. Although highly statistically significant, the actual dosage differences are relatively small. Nevertheless, this finding has been observed previously by others (23, 66) . Increasing androgen administration should theoretically increase intratesticular T, provided the maximal limit to T-dependent feedback inhibition of gonadotropin secretion is reached. Such minor increases in intratesticular testosterone are sufficient to promote spermatogenesis in rodents or primates (67) (68) (69) , although direct human evidence is lacking. We speculate that this mechanism may also partly explain why progestin coadministration, which allows lower androgen doses to be administered, is also associated with more complete spermatogenic suppression.
An unusual finding of the present analysis is that ethnicity exerts a time-differential effect on the rate of suppression of sperm output. Such an effect has been observed once before (20) . More information concerning the impact of androgen-progestin regimens on sperm output in other non-Asian and non-Caucasian ethnicities (particularly Africans and Hispanics) is needed. An optimized androgen-progestin combination might also overwhelm any ethnic differences in suppression of sperm output, but this question cannot be answered by the current data set.
Increasing age, increasing baseline T, and increasing baseline sperm concentration each decreases the rate of suppression, but effect sizes were small in relation to the expected range for each of these parameters and very close to a no-effect hazard ratio of unity. This assertion is especially true for age, wherein an interval of only two to three decades was included in the current data set. However, clinically important differences in suppression rates may occur when comparing extreme combinations of age, sperm concentration, and blood testosterone. Nevertheless, in general, these factors are less important than ethnicity and concurrent progestin administration.
Increasing body mass index (BMI) was also associated with nonsuppression, and this effect may be clinically important with marked obesity. Morbid obesity is associated with increased metabolic clearance of androgens in women, which is presumed to be due to reduced SHBG (70) because SHBG directly alters metabolic clearance of steroids in primates (71) . Reduced SHBG is also observed in obese men, and therefore, testosterone clearance is also likely to be increased. However, extrapolation to weight extremes is inadvisable because the vast majority of men included in this analysis were not markedly overweight (high body mass index was an exclusion criterion in most studies). Whether male hormonal methods are just as effective in completely suppressing sperm output in frankly obese men requires evaluation.
An important caveat in interpreting the present data are the comprehensive scope of this integrated analysis, which included exploratory studies in which the dose and/or methods of delivery of the androgen or progestin were suboptimal for spermatogenic suppression. For this reason, although 50% of men were observed to suppress their sperm output to 1 million/ml or less by 2-3 months, this is most likely an underestimate of the proportion of men who can achieve this degree of suppression of sperm output by this time. Indeed, modern androgen and androgenprogestin combinations report suppressibility in 80 -95%, not 50%, of men within 2-3 months (3, 4) , and these data compare favorably with the disappearance of sperm after vasectomy (72) . Therefore, the inclusion of exploratory studies limits interpre- tation of absolute suppressibility and attempting to summarize these mostly nonefficacy studies for this purpose is flawed (73) . However, we reasoned that a complete data set would enhance detection of more subtle predictors of the relative rate of suppression of sperm output, as was our goal here. Furthermore, our analysis suggests that reliable and timely contraception is a reasonable expectation for a wide range of couples of differing ethnicity, age, and other characteristics. Future research to improve timely suppression of sperm output may require initial coadministration of GnRH antagonists (31), optimization of progestin type and dose, or use of new synthetic androgen receptor modulators.
We conclude that androgen-progestin administration can suppress sperm output in a timely fashion to concentrations that are compatible with reliable contraception in most, but not all, men. The rate of suppression is comparable with that achieved after vasectomy. All available T preparations are broadly equivalent, although excessive T exposure may result in less complete spermatogenic suppression, presumably in the context of already maximal feedback suppression of gonadotropin output. Progestin coadministration is essential for timely and reliable suppression of spermatogenesis. Predicting which men will fail to adequately suppress sperm output is unlikely to be possible with conventional clinical or laboratory data. Whether pharmacogenetic factors may be helpful to determine responsiveness to hormonal contraceptive agents remains speculative.
